Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data

被引：0

作者：

Sanyal, Arun J. ^{[1
]}

Abdelmalek, Manal F. ^{[2
]}

Kowdley, Kris V. ^{[3
]}

Alkhouri, Naim ^{[4
]}

Harrison, Stephen A. ^{[5
]}

Schattenberg, Jorn M. ^{[6
]}

Gottwald, Mildred D. ^{[7
]}

Feng, Shibao ^{[7
]}

Agollah, Germaine D. ^{[7
]}

Hartsfield, Cynthia L. ^{[7
]}

Mansbach, Hank ^{[7
]}

Margalit, Maya ^{[8
]}

Loomba, Rohit ^{[9
]}

机构：

[1] Virginia Commonwealth Univ, Richmond, VA USA

[2] Mayo Clin, Rochester, MN USA

[3] Liver Inst Northwest, Seattle, WA USA

[4] Arizona Liver Hlth, Chandler, AZ USA

[5] Pinnacle Clin Res, San Antonio, TX USA

[6] Saarland Univ, Med Ctr, Homburg, Germany

[7] 89bio, San Francisco, CA USA

[8] 89bio, Rehovot, Israel

[9] Univ Calif San Diego, Sch Med, La Jolla, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-203

引用

页码：S607 / S608

页数：2